![ScibaseLogo_c0m70y90k0_neg[1]](https://barrier.scibase.com/wp-content/uploads/2022/10/scibaselogo-c0m70y90k0-neg1.png)
Nevisense AD
Creating a new standard in eczema care
Eczema: A global health problem
Atopic dermatitis (AD), the most common form of eczema, causes lifelong suffering for tens of millions of people worldwide.
20% of infants develop AD
They are up to 7 times more likely to develop asthma and allergies.
7% of adults suffer from AD
40% of them experience chronic symptoms, and some of those debilitating pain.
"The development collaboration with J&J is a milestone for SciBase. If successful, the combination of ease and unique predictive information could translate into broad adoption and open a significant consumer market for SciBase. An important step in shaping a future where medical technology is accessible, non-invasive, and personalized.”,
Simon Grant
CEO, SciBase
33% to 50% of adults with AD avoid social interactions because of their appearance.
Children with severe AD have fewer friends and spend more time alone than other children.
Nearly 40% of eczema patients report that they have turned down a job or an educational opportunity due to their disease.
![iStock-1137515007 [Converted]](https://barrier.scibase.com/wp-content/uploads/2022/10/istock-1137515007-converted.webp)
The challenge:
Clinicians simply do not have the tools to identify the right treatment for the right patient, at the right time.
”I can't sleep. I can't work. And I never know when it will flare up. I feel like I just have to suffer in silence.”
”It's heartbreaking to see the way people stare at my baby girl. Is this just the beginning? How will she go to day care next year?”
”It feels like 1,000 paper cuts on my skin. It's horrible. I haven't been able to sleep for weeks.”
Creating a new standard in eczema care
Nevisense will make it possible for clinicans to predict, measure and monitor AD by measuring the skin barrier.
By improving the management of eczema, we can help prevent unnecessary suffering and the development of subsequent atopic diseases for tens of millions of patients worldwide.
Why the skin barrier matters
Eczema is caused by a combination of skin barrier disruptions and immunological reactions. Until now, there has been no way to clinically quantify the degree of skin barrier dysfunction.
Identifying the right treatment
A new generation of biologic and topical treatments is emerging, putting clinicians under increased pressure to identify the severity of AD, monitor treatment outcomes and prescribe the right treatment for the right patient.
AD currently consumes more resources within dermatology than any other disease, including skin cancer. Treatments can be costly, as much as 30,000 USD annually for a single patient.
An objective method of assessment will make it possible to predict, measure and monitor the progression of AD.
Nevisense, an effective way for clinicians to:
PREDICT
the risk of infants developing AD before it occurs
MEASURE
skin barrier dysfunction to classify AD risk and severity
MONITOR
potential flare-ups and quantify patients' response to treatment over time
"I work every day with the management of different allergic diseases in children, and it is a growing problem. Allergic diseases have a natural progression with atopic dermatitis being the first to manifest, often already in infancy, followed by other allergic diseases, such as food allergy and allergic asthma. The ability to identify these children early will help to develop preventive strategies for allergic diseases, and Nevisense is an extremely promising method that has potential for early prediction of those children."
Dr. Caroline Roduit
PD Dr. med., PhD, University of Zurich | UZH · Children’s Hospital of Eastern Switzerland.
An established technology based on 25 years of research
The Nevisense platform utilizes a unique combination of Electrical Impedance Spectroscopy (EIS) and AI. It has been developed based on extensive research and clinical experience.
- Documented in 85 publications; including more than 5,000 patient cases.
- In use today in nearly 500 clinics; with more than 150,000 tests performed.
Our corporate site
Visit scibase.com to learn more on how Nevisense is beeing used in all indications.
Investor
SciBase is listed on the Nasdaq First North Exchange, visit our Investor Relations site to learn more.
Publications
Nevisense has been included in over 85 published studies. Download our publication list here.
The result: a new objective clinical standard to measure and manage eczema and associated skin disorders.
Contact us
"*" indicates required fields